Regen BioPharma, Inc.
RGBP
$0.00
$0.000.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -164.30% | 202.48% | -69.07% | -242.20% | -762.37% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 1.15% | -2.25% | -73.98% | 562.16% | -158.73% |
| Total Other Non-Cash Items | 157.79% | -248.72% | 141.29% | 72.31% | 245.58% |
| Change in Net Operating Assets | -167.86% | 591.92% | -136.26% | 179.02% | -300.87% |
| Cash from Operations | 61.87% | 68.06% | -23.69% | -185.71% | 44.66% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | 113.57% | -45.58% |
| Total Debt Repaid | -200.00% | 115.14% | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -73.93% | 229.55% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -59.25% | -55.71% | -41.62% | 306.79% | -45.58% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 100.00% | 93.38% | -195.87% | -- | -100.00% |